Specifically, in Rafferty v. Merck & Co., Inc., [4] the SJC held that plaintiffs who ingest the generic form of a drug may bring failure to warn
claims against the brand - name manufacturer of the drug if the brand - name
defendant acted recklessly by «intentionally fail [ing] to update the label on its drug while knowing or having reason to know of an unreasonable risk of
death or grave bodily injury associated with its use.»
This should help to preserve evidence, as well as immediately get a jump start on a
claim against a
defendant likely to ultimately face numerous
claims for injuries and wrongful
death stemming from the same incident.